NASDAQ:ZVSA ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis → Secret energy grid to power millions of homes (From Porter & Company) (Ad) Free ZVSA Stock Alerts $4.41 -0.34 (-7.16%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$4.41▼$4.9550-Day Range$4.02▼$7.5052-Week Range$3.94▼$141.89Volume26,282 shsAverage Volume270,418 shsMarket Capitalization$3.66 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get ZyVersa Therapeutics alerts: Email Address ZyVersa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,621.1% Upside$120.00 Price TargetShort InterestHealthy1.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($15.05) to ($25.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 stars 3.5 Analyst's Opinion Consensus RatingZyVersa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageZyVersa Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about ZyVersa Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.79% of the float of ZyVersa Therapeutics has been sold short.Short Interest Ratio / Days to CoverZyVersa Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ZyVersa Therapeutics has recently decreased by 4.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldZyVersa Therapeutics does not currently pay a dividend.Dividend GrowthZyVersa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZVSA. Previous Next 1.5 News and Social Media Coverage News SentimentZyVersa Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ZyVersa Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for ZVSA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ZyVersa Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ZyVersa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of ZyVersa Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.91% of the stock of ZyVersa Therapeutics is held by institutions.Read more about ZyVersa Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ZyVersa Therapeutics are expected to decrease in the coming year, from ($15.05) to ($25.45) per share.Price to Book Value per Share RatioZyVersa Therapeutics has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ZyVersa Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market Moving TrendsTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In About ZyVersa Therapeutics Stock (NASDAQ:ZVSA)ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.Read More ZVSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZVSA Stock News HeadlinesJune 2, 2024 | americanbankingnews.comZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 21.1%May 17, 2024 | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Earnings Estimates, EPS, and RevenueMay 16, 2024 | investorplace.comZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateMay 14, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionApril 29, 2024 | msn.comWhat's Going On With ZyVersa Stock?April 29, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseApril 29, 2024 | globenewswire.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseApril 4, 2024 | globenewswire.comZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesApril 3, 2024 | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Quotes and News SummaryMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic AdvancementsMarch 25, 2024 | globenewswire.comZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseMarch 14, 2024 | finance.yahoo.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024March 14, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024March 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Inflammatory and Metabolic Syndrome TreatmentsFebruary 29, 2024 | globenewswire.comZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityFebruary 28, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsFebruary 28, 2024 | globenewswire.comZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsFebruary 26, 2024 | msn.comWhat In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?February 26, 2024 | investorplace.comWhy Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?February 22, 2024 | finance.yahoo.comZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionFebruary 22, 2024 | globenewswire.comZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionFebruary 14, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesSee More Headlines Receive ZVSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZyVersa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/07/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZVSA CUSIPN/A CIK1859007 Webwww.zyversa.com Phone754-231-1688FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$120.00 High Stock Price Target$120.00 Low Stock Price Target$120.00 Potential Upside/Downside+2,560.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-552.24% Return on Assets-315.58% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$88.98 per share Price / Book0.05Miscellaneous Outstanding Shares830,000Free Float829,000Market Cap$3.74 million OptionableNot Optionable Beta0.70 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephen C. Glover (Age 64)Co-Founder, Chairman, CEO & President Comp: $775kMr. Peter Wolfe (Age 56)CFO & Secretary Comp: $477.5kMs. Karen A. Cashmere (Age 72)Chief Commercial Officer Comp: $410kMs. Melda Uzbil O'connellSenior Vice President of Corporate DevelopmentDr. Pablo A. Guzman FACC (Age 74)M.D., Chief Medical Officer, Senior VP of Medical Affairs & Chairman of Renal Scientific Advisory Board Key CompetitorsAkari TherapeuticsNASDAQ:AKTXTraws PharmaNASDAQ:TRAWFlora GrowthNASDAQ:FLGCGalectoNASDAQ:GLTOEdesa BiotechNASDAQ:EDSAView All Competitors ZVSA Stock Analysis - Frequently Asked Questions Should I buy or sell ZyVersa Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZyVersa Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZVSA shares. View ZVSA analyst ratings or view top-rated stocks. What is ZyVersa Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 1 year target prices for ZyVersa Therapeutics' stock. Their ZVSA share price targets range from $120.00 to $120.00. On average, they anticipate the company's stock price to reach $120.00 in the next year. This suggests a possible upside of 2,621.1% from the stock's current price. View analysts price targets for ZVSA or view top-rated stocks among Wall Street analysts. How have ZVSA shares performed in 2024? ZyVersa Therapeutics' stock was trading at $9.00 at the beginning of 2024. Since then, ZVSA stock has decreased by 51.0% and is now trading at $4.41. View the best growth stocks for 2024 here. When is ZyVersa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 19th 2024. View our ZVSA earnings forecast. How were ZyVersa Therapeutics' earnings last quarter? ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) issued its earnings results on Wednesday, May, 15th. The company reported ($4.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.70) by $0.83. When did ZyVersa Therapeutics' stock split? Shares of ZyVersa Therapeutics reverse split on Friday, April 26th 2024. The 1-10 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ZyVersa Therapeutics? Shares of ZVSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZVSA) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.